BOSTON– Solu Therapeutics has appointed Enda Moran, PhD, MBA, as Chief Operating Officer (COO), strengthening its executive team as the company advances its pipeline of novel therapies targeting disease-driving cells in cancer, immunology, and other serious conditions. The appointment comes as Solu progresses its lead program, STX-0712, through a Phase 1 clinical trial in patients with resistant or refractory chronic myelomonocytic leukemia (CMML) and other hematologic malignancies.
Dr. Moran brings over 30 years of experience in biomanufacturing and technical operations, having held leadership roles at GSK, Wyeth, and Pfizer, where he supported the development and global production of major commercial therapies, including Enbrel®, Trumenba®, Xyntha®, and Prevnar®13. He also led CMC and manufacturing operations at Northern Biologics, facilitating strategic acquisitions by AstraZeneca and Boehringer Ingelheim. Most recently, he served as CEO of Matrivax, overseeing a successful restructuring and completion of a Phase 1 trial.
In his new role at Solu, Dr. Moran will oversee core operational areas including chemistry manufacturing and controls (CMC), quality, program management, IT, and facilities. He will also play a key role in scaling the company’s proprietary CyTAC™ and TicTAC™ platforms—technologies designed to precisely eliminate pathogenic cells while enhancing therapeutic safety.
“As we advance STX-0712 and expand our platform capabilities, Enda’s expertise in scaling biologic therapeutics and navigating early-stage development will be instrumental,” said Philip J. Vickers, President and CEO of Solu Therapeutics. “His leadership will be vital as we build the infrastructure to support our clinical and regulatory milestones.”
Dr. Moran expressed enthusiasm for the company’s direction and scientific vision. “The CyTAC and TicTAC platforms are grounded in exciting science with the potential to transform outcomes for patients with limited treatment options,” he said. “I’m eager to help guide Solu through this next phase of growth and bring truly innovative therapies to the clinic.”
Solu’s platform technologies aim to reshape treatment strategies in oncology and immunology by targeting harmful cells with precision and minimizing off-target effects. The company continues to expand its clinical pipeline and operational footprint as it prepares for future development and commercialization stages.
